Kornimate/medical-research-clean huggingface dataset:
the effects of the intrapartum care model given in line with the recommendations of the world health organization (who)

Conditions: Birth Outcome, Adverse; Breast Feeding; Parenting

Summary: the objective of this study was to examine the impact of the intrapartum care model that adheres to the guidelines set forth by the world health organization (who) on several key outcomes, including the mother's maternal behavior towards her infant postpartum, breastfeeding self-efficacy, the success of breastfeeding, and the mother's readiness for hospital discharge.

the study was a randomized controlled trial. the study was conducted with 128 primiparous pregnant women (intervention group n=64, control group n=64) admitted to the maternity unit of a training and research hospital in a province in the central anatolia region of turkey. pregnant women in the intervention group were provided with intrapartum care in accordance with the who recommendations following the achievement of cervical dilatation reaching 5 cm. the control group was provided with only standard intrapartum and postpartum care. data were collected using a personal information form, a postpartum parenting behavior scale, a breastfeeding self-efficacy scale, a breastfeeding charting system and documentation tool (latch), and a hospital discharge readiness scale.

Eligibility criteria:
inclusion criteria: * being 18 years of age or older, * history of term pregnancy (38-42 weeks), * having a primiparous, * single, healthy, vertex positioned fetus, * having no complications that may cause dystocia in labor (such as contraction anomalies, birth object, * birth canal dystocia, dystocia related to the mother's psychology), * having a partner/husband, * history of cervical dilatation of 5 cm or more, * having a healthy newborn, * being able to speak and understand turkish. exclusion criteria: * being under 18 years of age, * having a diagnosed mental illness (depression, anxiety or other psychotic disorder, etc.), * having a chronic disease (hypertension, diabetes, etc.), * having maternal or fetal complications (oligohydramnios and polyhydramnios, placenta previa, pre-eclampsia, premature rupture of membranes, anomalies of presentation, intrauterine growth retardation, fetal anomaly, intrauterine death, fetal macrosomia, cord prolapse, etc.), * having any complication that prevents vaginal delivery (head-pelvis incompatibility, etc.), * having a history of elective cesarean section, * being pregnant with assisted reproductive techniques, * being multiparous,and having mastitis in the breast or having inverted nipples. * the study also excluded women who had undergone a cesarean section due to any complication (e.g., cord entanglement, fetal distress), * who experienced complications related to the postpartum period (e.g., uterine atony, hemorrhage), * and whose infant was admitted to the neonatal intensive care unit for any reason (e.g., respiratory distress).

Keywords: who intrapartum care model breastfeeding self-efficacy latch parenting behavior discharge readiness
connected yorkshire: a data-linkage study of pre-hospital, emergency department and out of hours service data

Conditions: Emergency and Urgent Care Pathways

Summary: there is increased demand on emergency departments (ed) across the uk. the services are becoming stretched and as a result waiting times are increasing and patient care is suffering. by linking together patient data from different hospitals and services across yorkshire, researchers are able to build a more complete picture of how emergency and urgent care (uec) services in the region function. this picture will help researchers understand the flow of patients through euc services, to understand what the most common health issues are and to better plan community services in the future. the anonymous data can help scientists understand euc services across an entire region and suggest improvements in a much more synchronised way. health service managers will also be able to understand how one ed in yorkshire compares to another. by re-using existing data researchers will also allow hospitals to learn lessons from each other so that each local service can improve and deliver better care for its patients. in the future, this information will help researchers to plan ahead and forecast disease outbreaks. the data used will, over time, tell a story that will help deliver better and more targeted care. the aim of the research project is to build a unique dataset based on expertise already being developed across the yorkshire and humber region. we will collect routine nhs data from a number of providers of euc and link the data to provide a coherent picture of euc demand. this rich data source will allow the euc services to be viewed as a whole system, enabling demand on the system by patients to be analysed as well as the flow of patients through the system.


Eligibility criteria:
inclusion criteria: * access urgent and emergency care services in yorkshire and the humber region between 2011 and 2017 exclusion criteria: * none
assessment of body composition and physical function

Conditions: Body Composition; Physical Function

Summary: sarcopenia, which is the loss of muscle mass and strength or physical function, naturally occurs in aging. in sarcopenic obesity, growth of muscle mass and increments in strength do not parallel weight gain, and places older adults at increased risk of falls, fractures, physical disability, frailty, and mortality from too low muscle strength relative to body size. the goal of the study is to assess body composition and physical function in older adults with obesity.

this is a cross-sectional study in 40 adults aged 60 to 80 years with obesity. body composition, physical function, and insulin resistance will be measured. subjects who satisfy the eligibility criteria and sign the informed consent will be enrolled. subjects will complete an assessment of body composition by bioelectrical impedance analysis and tests of physical performance. blood will be drawn for measurement of fasting glucose and insulin.

Eligibility criteria:
inclusion criteria: * body mass index \> 30kg/m2 * age 60 - 80 years exclusion criteria: * self-reported history of diabetes, or cancer or significant cardiovascular or hepatic or renal disease or dysfunction. * clinically significant gastrointestinal malabsorption syndromes such as chronic diarrhea, or celiac disease.
the utility of cell-free methylation markers in blood for hepatocellular carcinoma

Conditions: Serum Tumor Markers

Summary: patients with liver cancer expected to undergo radiofrequency ablation or transvascular embolization. relevant tumor markers (afp and methylation analysis) were performed. the two data are then counted and compared.

the subjects of this study were patients who were diagnosed with liver cancer by physicians based on aasld clinical criteria or pathological biopsy. patients are those who received radiofrequency ablation or transvascular embolization in national taiwan university hospital. which excludes weakness and inability to cooperate patients with blood test, under the condition of fully informed consent, complete blood test related tumor indicators (afp and methylation analysis). the two data are then counted compare.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with liver cancer by aasld clinical criteria or pathological sections are planned to receive treatment at national taiwan university hospital liver local treatment such as radiofrequency ablation or transvascular embolization. 2. be over 20 years old. 3. under the condition of informed consent, willing to sign the consent form of the subjects. exclusion criteria: 1. patients who are weak and unable to cooperate with blood test. 2. kidney dysfunction, serum creatinine greater than 1.5mg/dl, it is judged that computer tomography or mri cannot be performed vibrate the injector.
the forteo alendronate comparator trial

Conditions: Osteoporosis

Summary: the main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (bmd) and other osteoporosis factors in postmenopausal women with osteoporosis.


Eligibility criteria:
inclusion criteria: * postmenopausal women with osteoporosis. * ambulatory, 5 years or more past menopause. * bmd t score between -2.5 and -4.0 at the lumbar spine or femoral neck. * normal or clinically insignificant abnormal laboratory values, including serum calcium, parathyroid hormone (pth) 1-84, 25-hydroxyvitamin d, and alkaline phosphatase. exclusion criteria: * prior treatment with pth or a pth analogue. * treatment with bisphosphonates within 12 months, anabolic corticosteroids or calcitriol or vitamin d analogues or agonists within 6 months, estrogens or selective estrogen receptor modulators within 3 months, or calcitonin within 2 months; therapeutic doses of fluoride; systemic corticosteroid use within 1 month or for more than 30 days in the prior year; use of anticoagulants within 1 month. * history of diseases other than postmenopausal osteoporosis that affect bone metabolism. * history of an increased risk of osteosarcoma (ie, patients with paget disease of bone, previous skeletal exposure to external beam radiotherapy, or previous malignant neoplasm involving the skeleton). * malignant neoplasms within 5 years; carcinoma in situ of the uterine cervix within 1 year. * nephrolithiasis or urolithiasis within 2 years, or impaired renal function. * abnormal uncorrected thyroid function. * liver disease or clinical jaundice. * alcohol or other drug abuse. * poor medical or psychiatric risk for treatment.
lansoprazole in preterm infants with gastroesophageal reflux (ger)

Conditions: Premature Infants; Gastroesophageal Reflux

Summary: this study is crossover study to evaluate safety and efficacy of lansoprazole in preterm infants with gastroesophageal reflux.


Eligibility criteria:
inclusion criteria: * preterm infant * symptoms suspecting gastroesophageal reflux exclusion criteria: * unstable general conditions due infection or acute illness * congenital anomaly in upper gastrointestinal tract including esophagus * drug history of h2, proton pump inhibitor, blocker during last 1 week * medication of warfarin, carbamazepine, phenytoin, rifampin * inappropriate clinical conditions judged by researchers
the effect of an physician-nurse supplementary triage assistance team on emergency department patient wait times

Conditions: Emergencies

Summary: the primary objective of this study is to investigate whether the introduction of a physician-nurse supplementary triage assessment team (mdrn stat) is effective in improving time-based performance indicators for wait times. secondary objectives will examine the quality of patient care and health care worker satisfaction and the cost-effectiveness of the program

in 2007, the ontario ministry of health and long-term care (mohltc) declared emergency department wait-times a government priority. the crisis of overcrowding and access block has become an international epidemic, affecting developing countries in europe, north america, and australasia. the mohltc has targeted 23 ontario hospitals' prolonged wait times. sunnybrook health sciences center has been selected. therefore, this is a quality improvement study of patient wait-times and care. during a 20-week period, the mdrn stat will be present on randomly chosen weekdays (8:00-16:00) for 50 shifts. wait-times, such as time from triage time to: physician assessment, stretcher occupation, treatment orders (drugs), investigation orders (laboratory, diagnostic imaging), investigation acquisition (diagnostic imaging), consultation, bed request, discharge from ed (i.e. length of stay (los)) time, will be analyzed. in addition, the left-without-being-seen rate (lwbs) and rate of return will be analyzed. these results will be compared to the ontario wait-time strategy p4r targets, as well as the canadian triage acuity scale (ctas guidelines). economic analysis of this intervention will be done. the hospital will independently perform patient satisfaction surveys. health care worker satisfaction survey data will be analyzed.

Eligibility criteria:
inclusion criteria: * patients arriving from 8:00-14:30 during a day here a mdrn stat is assigned exclusion criteria: * none

Keywords: emergency department wait times physician nurse at triage overcrowding costeffectiveness
sequelae of developmental dysplasia of the hip

Conditions: Developmental Dysplasia of the Hip; Hip Dysplasia

Summary: the aim of this study is to assess long term effects of developmental dysplasia of the hip (ddh) to overall health and quality of life later in life. we compare hip radiographs, hip symptoms, clinical examination, head asymmetry, dental examination and intraoral scans of 170 children and young adults treated for ddh in their childhood with age and sex matched controls.

developmental dysplasia of the hip (ddh) is the most common musculoskeletal disorder in infancy. however there are few reports of long term effects of successfully treated ddh. incidence of ddh in neonatal period is approximately 1-10/1000 depending on screening protocols used, the age of the infant during screening and which ultrasonographic findings are considered normal and which ddh. the prevalence of hip dysplasia in adult population is grossly 4 % when using wibergs centre-edge (ce) ≤ 20° as definition of dysplasia. it is still unclear, what is the relation between adult acetabular dysplasia and developmental dysplasia in children. hip dysplasia overall is a major contributing factor in hip osteoarthrosis and total hip replacement in young adults. the aim of this study is to assess long term effects of developmental dysplasia of the hip to overall health and quality of life later in life. we compare hip radiographs, hip symptoms, clinical examination, head asymmetry, dental examination and intraoral scans of 170 children and young adults treated for ddh in their early childhood with age and sex matched controls.

Eligibility criteria:
inclusion criteria for person treated for ddh: * ddh has been diagnosed by clinical examination, ultrasound examination or by radiological examination and treatment begun before age of 1,5 years. * treated in oulu university hospital exclusion criteria: * neurological or developmental condition which can influence hip development such as cerebral palsy or spina bifida * other significant congenital anomalies of musculoskeletal system such as club feet

Keywords: developmental dysplasia of the hip hip dysplasia occlusal defect
"galectin-3 as a marker of subclinical inflammation in fmf"

Conditions: Ailesel Akdeniz Ateşi

Summary: the goal of this observational study is to learn about the relationship between serum galectin-3 levels and subclinical inflammation in patients with familial mediterranean fever (fmf). the main questions it aims to answer are: * are serum galectin-3 levels higher in fmf patients compared to healthy controls? * is there a positive correlation between serum galectin-3 levels and serum amyloid a (saa) protein levels in fmf patients? participants will: * provide blood samples to measure serum galectin-3 and saa levels. * complete a sociodemographic and clinical data form. * fill out the fmf quality of life (qol) scale. researchers will compare fmf patients and healthy controls to see if there are significant differences in serum galectin-3 levels and to determine the correlation between galectin-3 and saa protein levels in fmf patients.


Eligibility criteria:
inclusion criteria: * for the patient group: 1. aged between 18 and 65 years, 2. able to provide written informed consent for the study, 3. literate, 4. diagnosed with familial mediterranean fever (fmf) according to the tel hashomer criteria and not currently experiencing an attack (with at least 15 days since the last attack). * inclusion criteria for the healthy control group: 1. aged between 18 and 65 years, 2. able to provide written informed consent for the study, 3. literate. exclusion criteria: * exclusion criteria for the patient group: 1. presence of known inflammatory diseases other than fmf, 2. presence of known systemic, chronic, severe medical conditions, 3. presence of active infection, 4. conditions affecting cognitive functions such as mental retardation, delirium, dementia, epilepsy, and alcohol or substance use disorders, 5. being pregnant or in the lactation period. * exclusion criteria for the healthy control group: 1. presence of known systemic, chronic, severe medical conditions, 2. presence of inflammatory diseases, 3. presence of active infection, 4. conditions affecting cognitive functions such as mental retardation, delirium, dementia, epilepsy, and alcohol or substance use disorders, 5. being pregnant or in the lactation period. -

Keywords: galekti̇n-3 subclinical inflammation
effects of co-treatment on endometrial abv3-integrin expressions in women with recurrent implantation failure

Conditions: Miscarriage, Recurrent

Summary: to compare the abv3-integrin expression in endometrium tissue among rif women between the gnrh analogue with aromatase inhibitor (group a) , gnrh analogue with progesterone (group b) and gnrh analogue alone as control group (group c)

i. to determine the abv3-integrin expression isolated from endometrium tissue from women with rif prior to medical therapy. ii. to determine the abv3-integrin expression isolated from endometrium tissue from group a, group b and group c following the medical therapy. iii. to compare the abv3-integrin expression from endometrium tissue obtained from group a, b and c following the medical therapy. iv. to compare the implantation rates among group a, b and c following the medical therapy. v. to compare the ongoing pregnancy among group a, b and c following the medical therapy

Eligibility criteria:
inclusion criteria: * women of 18 to 40 years of age * no significant pre-existing major medical. * diagnosed as recurrent implantation failure - at least two or more failure of achieving pregnancy following embryo transfer (et) despite the optimum endometrial thickness and good quality of embryo (unexplained). * regular menstrual cycle atleast 3 months prior to treatment * not taking any hormonal treatment for atlest 3months prior to recruitment * agreed to participate exclusion criteria: * concurrent significant pre-existing major medical conditions such as uncontrolled diabetes, active systemic lupus erythematosus (sle) or anti phospholipid syndrome (aps) that will interfere with implantation. * poor quality of embryo * suboptimal endometrial thickness(\<8mm) during the embryo transfer (et). * on hormonal therapy prior to recruitment. * not agreed to participate
changes in anthropometric, biochemical and dna damage parameters after 3-weeks vlcd in severely obese patients

Conditions: Obesity; Weight Loss; DNA Damage

Summary: obesity manifest with inflammation, hyperglycaemia and dyslipidaemia. these conditions disturb redox system by generating excessive reactive oxygen species (ros) and causing oxidative stress (os) leading to dna damage. very low calorie diet (vlcd) have rapid positive effect on weight loss, glucose homeostasis, inflammation and os. the aim of study is to test the influence of 3-weeks vlcd on anthropometric, biochemical and genomic parameters in class ii and iii obesity patients.

obesity is a chronic disease associated with chronic inflammation, insulin resistance, dyslipidemia, oxidative stress and increased risk for type 2 diabetes, cardiovascular disease, stroke and multiple cancer types. oxidative stress can lead to base lesions of dna which could be detected with alkine comet assay and its version with use of formamidopyrimidine dna glycosylase-endonuclease enzyme in fresh or frozen small volume samples. dietary caloric restriction has beneficial effects on insulin sensitivity, inflammation, oxidative stress and dna repair. very low calorie diet (vlcd) data are scarce, especially on the changing levels of dna damage.this study will assess the effect of a three-week vlcd used in special hospital for extended treatment of duga resa in individuals with bmi ≥ 35kg/m2 on the level of primary and oxidative dna damage as well as body composition and biochemical parameters.

Eligibility criteria:
inclusion criteria: * body mass index ≥ 35 kg/m2 exclusion criteria: * pregnancy * actual tumor diseases * recent diagnostic or treatment exposures to ionizing radiation in the period of one year * individuals not willing to stay 3 weeks under supervision under full 24 h surveillance from the medical stuff

Keywords: obesity very low calorie diet alkine comet assay fpg oxidative comet assay dna damage
vitreous detachment and glaucoma progression

Conditions: Glaucoma; Posterior Vitreous Detachment

Summary: posterior vitreous detachment is a common event. with optical coherence tomography, the investigators can precisely follow the stage of posterior vitrous detachment. in this study, the investigators investigate if the loss of contact between the vitreous and the fovea is the start of glaucoma progression.


Eligibility criteria:
inclusion criteria: * patient with glaucoma * at least 4 years of follow up * at least 6 visual fields * at least 4 optical coherence tomographies exclusion criteria: * pars plana vitrectomy * others ophtalmological or neurological disease which can modify visual fields

Keywords: glaucoma vitreous progression
generating behavior change, an integrative health coaching and genetic risk testing pilot

Conditions: Coronary Heart Disease Risk

Summary: the purpose of this 4 group (2x2) pilot randomized controlled trial is to test the feasibility and logistics of incorporating genetic risk information (9p21)into standard coronary heart disease (chd) risk counseling or health coaching intervention (or both) in primary care at 2 duke clinics.


Eligibility criteria:
inclusion criteria: * age 18+, * presence of at least one of the following: * fpg \> 100, * hba1c \> 5.7%, * diabetic, * ldl \> 129, * triglycerides \> 150, * total cholesterol \> 200, * sbp \> 130, * bmi \> 25, * able to speak and understand english, * able and willing to give informed consent exclusion criteria: * diagnosed chd (mi or documented coronary artery disease), * inability to ambulate or participate in physical activity, * serious chronic disease related complications, * current participation in a risk communication study for chronic disease,

Keywords: coronary heart disease cardiovascular disease risk